Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor

Dimerization is recognized as a crucial step in the activation of many plasma membrane receptors. However, a growing number of receptors pre-exist as dimers in the absence of ligand, indicating that, although necessary, dimerization is not always sufficient for signaling. The p75 neurotrophin recept...

Full description

Saved in:
Bibliographic Details
Published inJournal of cell science Vol. 122; no. 18; pp. 3351 - 3357
Main Authors Vilar, Marçal, Charalampopoulos, Ioannis, Kenchappa, Rajappa S, Reversi, Alessandra, Klos-Applequist, Joanna M, Karaca, Esra, Simi, Anastasia, Spuch, Carlos, Choi, Soyoung, Friedman, Wilma J, Ericson, Johan, Schiavo, Giampietro, Carter, Bruce D, Ibáñez, Carlos F
Format Journal Article
LanguageEnglish
Published England The Company of Biologists Limited 15.09.2009
Company of Biologists
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Dimerization is recognized as a crucial step in the activation of many plasma membrane receptors. However, a growing number of receptors pre-exist as dimers in the absence of ligand, indicating that, although necessary, dimerization is not always sufficient for signaling. The p75 neurotrophin receptor (p75NTR) forms disulfide-linked dimers at the cell surface independently of ligand binding through Cys257 in its transmembrane domain. Here, we show that crosslinking of p75NTR dimers by cysteine-scanning mutagenesis results in constitutive, ligand-independent activity in several pathways that are normally engaged upon neurotrophin stimulation of native receptors. The activity profiles of different disulfide-crosslinked p75NTR mutants were similar but not identical, suggesting that different configurations of p75NTR dimers might be endowed with different functions. Interestingly, crosslinked p75NTR mutants did not mimic the effects of the myelin inhibitors Nogo or MAG, suggesting the existence of ligand-specific activation mechanisms. Together, these results support a conformational model of p75NTR activation by neurotrophins, and reveal a genetic approach to generate gain-of-function receptor variants with distinct functional profiles.
Bibliography:Author for correspondence (carlos.ibanez@ki.se)
Present address: Department of Pharmacology, Faculty of Medicine, University of Crete, Greece (I.C.), and Service of Neurology, Research Center, Hospital 12 de Octubre, Madrid, Spain
We thank Masami Kojima and Phyllis Dan for purified proBDNF, Phil Barker for MC192 antibody, and Moses Chao (Skirball Institute, New York, NY), Toshihide Yamashita (Osaka University, Osaka, Japan), Anders Nykjær (Aarhus University, Aarhus, Denmark) and Daniel Lee (Biogen, Boston, MA) for RIP2, RhoGDI, sortilin and Lingo-1 expression plasmids. This work was supported by grants from the Swedish Foundation for Strategic Research, the Swedish Research Council (33X-10908-10A and Linné program), the Vth Framework Program of the European Union (QLG3-CT-1999-00573), and the National Institutes of Health (1 R01 MH071624-01A2). R.S.K. and B.D.C. were supported by the National Institutes of Health (R01 NS038220), A.R. and G.S. by Cancer Research UK. Deposited in PMC for release after 12 months.
Present address: Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
ISSN:0021-9533
1477-9137
1477-9137
DOI:10.1242/jcs.055061